Gilead Sciences Inc. (GILD)
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.
US FDA approves Gilead's liver disease drug
The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.
Gilead Posts Solid Revenue in Q2
Revenue of $7.0 billion, up 6% excluding Veklury. Non-GAAP diluted EPS of $2.01.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Carter Gould - Barclays Michael Yee - Jefferies Brian Abrahams - RBC Capital Markets Chris Schott - JPMorgan Steven Seedhouse - Raymond James Tim Anderson - Wolf Research Salveen Richter - Goldman Sachs Olivia Brayer - Cantor Fitzgerald Operator Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.34 per share a year ago.
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Gilead stock is nearing a breakout after the company reported better-than-expected second-quarter sales and profit.
Gilead quarterly profit beats Street estimates, revenue up 5%
Gilead Sciences on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
After a disastrous performance in the first half of 2024, Gilead Sciences stock has rebounded strongly since mid-June. With Gilead Sciences due to report its Q2 results on Thursday, it's a good time to assess what we can expect and whether the rebound was justified. I will specifically discuss Gilead's novel GLP-1 receptor agonist, GS-4571, and other news that has emerged recently.
Countdown to Gilead (GILD) Q2 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
